Literature DB >> 11069227

The possible role of hepatitis A virus in the pathogenesis of atherosclerosis.

J Zhu1, A A Quyyumi, J E Norman, R Costello, G Csako, S E Epstein.   

Abstract

The possible association between hepatitis A virus (HAV) infection and coronary artery disease (CAD) was studied. Blood from 391 patients undergoing coronary angiography was tested for serum IgG antibodies to HAV and C-reactive protein (CRP). Of the 391 patients, 205 (52%) had anti-HAV IgG antibodies. CAD prevalence was 74% in HAV-seropositive and 52% in HAV-seronegative patients (P<.0001); significance persisted after adjustment for either traditional CAD risk factors or for risk factors plus other infectious agents (cytomegalovirus, Chlamydia pneumoniae, Helicobacter pylori, and herpes simplex virus). In addition, CRP levels were significantly higher in HAV-seropositive than in HAV-seronegative patients (P=. 013) in both univariate and multivariate analyses. Logistic regression analysis demonstrated that HAV seropositivity is an independent predictor of risk for CAD and elevated CRP levels. HAV infection is therefore associated with CAD, which raises the possibility that this virus may play a causal role in atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069227     DOI: 10.1086/317613

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

Review 1.  Role of infectious and immune factors in coronary and cerebrovascular arteriosclerosis.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

Review 2.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

3.  Association of influenza virus infection and inflammatory cytokines with acute myocardial infarction.

Authors:  Xiuru Guan; Wei Yang; Xijuan Sun; Lanfeng Wang; Benjiang Ma; Hongyuan Li; Jin Zhou
Journal:  Inflamm Res       Date:  2012-02-29       Impact factor: 4.575

Review 4.  Chronic infections and atherosclerosis/thrombosis.

Authors:  Prediman K Shah
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

5.  Viral and bacterial DNA in carotid atherosclerotic lesions.

Authors:  S Watt; B Aesch; P Lanotte; F Tranquart; R Quentin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-15       Impact factor: 3.267

6.  Hepatitis B virus infection and coronary atherosclerosis: results from a population with relatively high prevalence of hepatitis B virus.

Authors:  De-Yan Tong; Xiao-Hua Wang; Cong-Feng Xu; Ying-Zhen Yang; Si-Dong Xiong
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

7.  Influenza virus infection and risk of acute myocardial infarction.

Authors:  Xiu-Ru Guan; Xin Li; Xiao-Min Xin; Li-Xin Jiang; Lan-Ying Cui; Lan-Feng Wang; Hong-Yuan Li
Journal:  Inflammation       Date:  2008-08       Impact factor: 4.092

8.  Individual pathogens, pathogen burden and markers of subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Moyses Szklo; Jingzhong Ding; Michael Y Tsai; Mary Cushman; Joseph F Polak; João Lima; R Graham Barr; A Richey Sharrett
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2009-10       Impact factor: 2.160

9.  The influence of persistent pathogens on circulating levels of inflammatory markers: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Aydin Nazmi; Ana V Diez-Roux; Nancy S Jenny; Michael Y Tsai; Moyses Szklo; Allison E Aiello
Journal:  BMC Public Health       Date:  2010-11-17       Impact factor: 3.295

Review 10.  Infectious burden and atherosclerosis: A clinical issue.

Authors:  Rosa Sessa; Marisa Di Pietro; Simone Filardo; Ombretta Turriziani
Journal:  World J Clin Cases       Date:  2014-07-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.